The Filing Desk

Wave Life Sciences

WVE · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

WVE · Last close · November 13, 2026
$3.13
Value Wave Life Sciences yourself

Wave Life Sciences' revenue fell 60.5% to $43 million in fiscal 2025. Its operating margin was −504.1%, down from −101.9% a year earlier. Free cash flow was −$188 million. The diluted share count rose 22.0%.

WAVE LIFE SCIENCES, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-073472 Updated
Revenue
$43M
60.5%
Operating margin
−504.1%
402.1 pts
Net income
−$204M
 
Free cash flow
−$188M
 
Return on equity
−56.2%
21.7 pts
Market cap
$639M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Wave Life Sciences does

Wave Life Sciences is a clinical-stage biotechnology company with no approved products. It develops RNA medicines, which are drugs built from short pieces of genetic material that either silence a faulty gene's message or correct it. Its platform, called PRISM, uses chemistry changes it designed to make these molecules last longer and reach the right tissues without complex delivery carriers such as lipid nanoparticles or viruses.

Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and a genetic liver disease (WVE-008). It also has clinical programs for Duchenne muscular dystrophy and Huntington's disease, and several earlier programs. Its tools include RNA interference and RNA editing, which uses enzymes already inside cells.

Wave earns no product revenue. It funds its work by raising money and through collaborations with partners, which can pay it when programs reach milestones. It is incorporated in Singapore. It competes with other drug developers in each disease area it targets.

Its biggest risks, as it describes them

  • It has a history of losses, expects more, and needs substantial additional funding.
  • Its approach to RNA medicines is new and may never lead to a product that can be sold.
  • Its trials can be delayed by slow patient enrollment or fail to meet regulators' standards.
  • It relies on collaboration partners and on outside companies to run studies and trials.
  • It may not obtain or protect patent rights or secure marketing approval for its drug candidates.
From Wave Life Sciences's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Wave Life Sciences lost money in fiscal 2025: a net loss of $204 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments15188200302602
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio2.5x1.4x1.3x2.9x6.5x
Quick ratio2.5x1.4x1.3x2.9x6.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Wave Life Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Wave Life Sciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 402,987.0%−144.7%−501.0%
Altman Z''−12.46−6.961.15
Accruals ratio−18.1%17.2%−3.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Wave Life Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Wave Life SciencesFY25−60.5%−504.1%−440.5%———
Editas MedicineFY2525.4%−394.9%−409.3%——2Compare
Protagonist TherapeuticsFY25−89.4%−343.6%121.9%———Compare
SepternaFY254,174.5%−148.6%238.7%———Compare
Kymera TherapeuticsFY25−16.7%−891.1%−597.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2414162041411310843
Revenue growth877.0%149.4%289.1%10.9%25.6%104.0%−91.1%3,005.1%−4.4%−60.5%
Gross profit——————————
Research and development4179134175131122116130160183
Operating income−56−102−160−208−153−127−163−68−110−215
Net income−56−102−147−194−150−122−162−58−97−204
Diluted EPS (US$)−2.44−3.85−5.06−5.72−3.82−2.36−2.05−0.54−0.70−1.21
Diluted shares (millions)23262934395279106138169
Cash flow
Cash from operations−32−84−23−188−116−89−128−19−151−188
Capital expenditure619104111111
Free cash flow−37−103−33−192−117−90−129−21−152−188
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation7121620141617101325
Balance sheet at fiscal year end
Cash and short-term investments15014217514718415188200302602
Debt incl. finance leases——————————
Total assets165182296284279207146275352638
Total liabilities2234215213189167184227135112
Shareholders' equity13514073648332−4540210518
Margins and ratios
Gross margin——————————
Operating margin−3,752.2%−2,764.3%−1,106.7%−1,303.4%−763.9%−310.1%−4,459.3%−60.0%−101.9%−504.1%
Net margin−3,748.2%−2,753.2%−1,017.4%−1,211.5%−746.7%−298.4%−4,434.7%−50.8%−89.6%−478.3%
Free cash flow margin−2,524.7%−2,768.8%−227.6%−1,202.2%−584.4%−218.6%−3,539.1%−18.1%−140.3%−440.5%
Rule of 40 (growth + FCF margin)−1,647.7%−2,619.4%61.6%−1,191.3%−558.7%−114.6%−3,630.2%2,987.0%−144.7%−501.0%
Return on capital——————————
Return on equity−38.6%−74.4%−137.7%−282.5%−204.6%−212.1%——−77.9%−56.2%
Return on assets−33.7%−58.8%−61.4%−66.8%−53.2%−50.3%−91.6%−27.3%−30.9%−41.3%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Wave Life Sciences' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Wave Life Sciences.